Adursal

Quick links to important sections

Adursal

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adursal

What is Adursal? Definition and Identity

Property Description
Active ingredient Ursodiol (Ursodeoxycholic Acid or UDCA)
Form Oral preparations (capsules, tablets)
Pharmacological class Cholelitholytic and Hepatoprotective agent
General purpose Modifies bile composition and protects liver cells
Origin Semisynthetic derivative

Adursal is a prescription medicine whose sole active component is Ursodiol, formally known as Ursodeoxycholic Acid (UDCA). This substance is administered via the oral route and serves as a fundamental building block in managing certain issues within the biliary system. Ursodiol is a semisynthetic derivative of a naturally occurring secondary bile acid, structurally distinct due to its highly hydrophilic nature, which is a key property in its therapeutic action. This specific, single-ingredient composition is clinically recognized for its low systemic toxicity when compared to many of the body's native bile acids.

Classification and General Purpose

Adursal is principally classified as a cholelitholytic agent and a hepatoprotective agent, designations reflecting its dual action in the body's digestive and metabolic systems. Its general purpose is to chemically alter the composition of bile and provide cellular defense for the liver. Ursodiol is a medication that alters cholesterol secretion into the bile, making the bile less likely to form stones. This means the medication helps reduce the saturation of bile with cholesterol, making the environment unfavorable for the crystallization of cholesterol-rich gallstones. Ursodiol is also utilized in managing cholestatic liver diseases by displacing more toxic bile acids and protecting hepatocytes.

Adursal's Pharmaceutical Form and Delivery

Adursal is consistently formulated as a single-ingredient product designed for oral administration. The medication is commonly supplied in solid dosage forms, including capsules and tablets, compounded using standard solid dosage excipients. This form ensures the efficient transport of the Ursodiol to the liver, where it exerts its necessary cytoprotective effect on the biliary tract. Adursal, as a specific preparation, typically targets the adult patient population with indications related to bile composition and liver support, maintaining the high standards of pharmaceutical grade UDCA required for chronic therapy.

Regulatory References

  1. NIH: Ursodiol (Ursodeoxycholic Acid) LiverTox
  2. MedlinePlus: Ursodiol Drug Information

What side effects are possible with Adursal?

Possible Side Effects and Safety Information

The regulatory documentation for Adursal (Ursodiol) defines a specific set of adverse reactions and safety patterns, primarily concerning the gastrointestinal and hepatobiliary systems. The officially listed adverse reactions are categorized by the frequency with which they are reported in clinical use.

Adverse effects associated with the use of Ursodiol are most frequently documented within the Gastrointestinal disorders system-organ class. Diarrhoea and the occurrence of soft stools are classified as Very Common events, meaning they affect more than 1 in 10 patients. These gastrointestinal effects are reported to be dose-dependent and typically transient (temporary), often resolving upon an adjustment of the intake amount.

Less frequently, effects are noted in the Skin and Subcutaneous Tissue Disorders system, where Pruritus (itching) and Urticaria (hives) are classified as Uncommon reactions. In Very Rare cases, an exacerbation of psoriasis has been documented. Within the Hepatobiliary disorders system, an increase in blood levels of liver enzymes (such as ALT and AST) may be observed during treatment, and a calcification of the gallstones has been classified as a Rare event.

High-level safety constraints define certain patient conditions under which the medication should not be used. These contraindications include the presence of acute inflammation of the gallbladder or biliary tract, a complete occlusion of the biliary tract, or the existence of calcified cholesterol gallstones. Furthermore, severe right upper quadrant abdominal pain is listed as a serious adverse reaction in regulatory documentation.

Overdose and Emergency Response

Adursal Overdose and when to seek help

The regulatory information regarding Adursal (Ursodiol) overdose centers on limited clinical experience and the most likely physiological manifestation.

Documented Clinical Presentation

Official prescribing information indicates that no cases of accidental or intentional overdosage in humans have been formally reported. The primary clinical presentation anticipated from an excessive dose is severe diarrhoea. Other severe symptoms are considered unlikely because the absorption of ursodiol decreases as the dose increases, leading to increased excretion from the body. The documentation notes that no specific antidote is known for Ursodiol overdosage.

Emergency Actions Mandated by Regulators

Regulators mandate immediate action for a suspected overdose. You must seek immediate medical attention by contacting a healthcare professional or a regional poison control center. Urgent medical care is required if the person exhibits signs of a life-threatening emergency, such as trouble breathing, collapse, seizure, or inability to be awakened. The official guidance for managing severe or persistent diarrhoea caused by overdosage involves reducing the dose or, if necessary, discontinuing therapy under medical supervision.

Therapeutic Uses of Adursal

What Adursal Treats: Main Uses and Benefits

Adursal, with its active ingredient Ursodiol, is commonly used across therapeutic domains involving systemic imbalance within the liver and biliary system. The medication is applied in addressing conditions that primarily affect the liver and gallbladder. The main indications are commonly used to help with the therapeutic management of Primary Biliary Cholangitis (PBC) and to address structural manifestations like cholesterol gallstones.

Therapeutic Support and Benefit

For patients with PBC, Adursal is considered relevant for managing the progressive aspects of the condition and contributes to favorable long-term outcomes. This supportive therapy helps maintain a sense of stability when symptoms are more noticeable. For gallstone disease, the benefit is primarily structural, as the drug plays a role in managing these conditions by helping to reduce or dissolve existing stones. It is applied in addressing this structural risk for obese patients undergoing rapid weight loss, helping to ease the overall symptom load by preventing disruptive complications. “Supports the patient during difficult episodes by easing distress and assists with maintaining functional stability in the biliary system.”

Quick Fact: Relevant for Biliary Imbalance

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Adursal (Ursodiol) eligibility is strictly defined by regulatory bodies based on a patient's underlying health status and demographics.

Populations for Whom Use is Contraindicated

The medication must not be used by individuals with complete biliary obstruction or acute inflammation of the gallbladder or biliary tract. Contraindications also include patients with a non-functioning gallbladder, those experiencing frequent biliary colic, and individuals with calcified gallstones when treating gallstone disease. Use is also strictly prohibited in cases of known hypersensitivity to the drug or its components, or for patients with active gastric or duodenal ulcers.

Age-Related and Conditional Eligibility

Adursal is approved for adults for primary indications like Primary Biliary Cholangitis (PBC). Its use in the general pediatric population is not established, though it is approved for certain CF-associated hepatobiliary disorders in children aged 6–18 in some regions. Use is not recommended during pregnancy or lactation, and women of childbearing potential must use reliable contraception. Use is also contraindicated in patients with conditions like inflammatory bowel disease (regional ileitis) which affect bile acid recirculation.

What should I know about interactions with other medicines?

Adursal Interactions with other medicines and products

Adursal (Ursodiol) has officially documented interaction patterns primarily concerning reduced absorption and therapeutic antagonism, as defined in regulatory labeling. The co-administration of certain medicinal products is restricted to maintain the effectiveness of Adursal.

Interactions Affecting Exposure and Efficacy

Interacting Class/Product Official Interaction Pattern Constraint/Restriction
Bile Acid Sequestering Agents (e.g., Cholestyramine) Reduce the absorption and systemic exposure of Adursal. Mandatory Timing Rule: Must be separated by at least 1 hour.
Aluminum-based Antacids (e.g., Aluminum Hydroxide) Interfere with Adursal's action by binding bile acids. Mandatory Timing Rule: Must be separated by at least 1 hour.
Estrogens and Clofibrate Promote hepatic cholesterol secretion, which counteracts Adursal's therapeutic effect. Avoidance/Restriction: Counteracts intended efficacy.

Other Documented Exposure Changes

Adursal may decrease the absorption and resulting systemic exposure of certain co-administered medications, including the immunosuppressant Cyclosporine. Additionally, regulatory information notes potential decreases in the exposure of other medicinal products, such as Dapsone and Nitrendipine. The official labeling contains no explicit warnings or restrictions regarding interactions with alcohol, herbal products, or supplements.

Mechanism of Action

Adursal is a monoclonal antibody that targets the Receptor Activator of Nuclear Factor kappaB Ligand (RANKL) signaling pathway. It functions as an inhibitor by binding with high affinity and specificity to the circulating and membrane-bound forms of the RANKL protein. This binding sequesters RANKL, preventing it from interacting with its receptor, RANK, located on the surface of osteoclast precursors and mature osteoclasts. By blocking this essential ligand-receptor interaction, Adursal interrupts the molecular signal necessary for osteoclast differentiation, maturation, and survival. The intracellular consequence of this signaling inhibition is the rapid decrease in the number and function of osteoclasts. This downstream cascade leads to the direct suppression of bone resorption, thereby modulating the overall rate of bone turnover at the system level.

Dosage and Administration Information

How to Use Adursal: Official Administration Guidelines

Adursal (Ursodiol) is a prescription medicine used according to specific, standardized instructions established for its use. The primary and sole route of administration is oral.

Administration and Dosing Principles

Feature Official Usage Principle
Dose Calculation The total daily dose is typically determined by body weight (13 to 15 mg/kg/day for Primary Biliary Cholangitis [PBC], or 8 to 10 mg/kg/day for gallstone dissolution). A fixed dose of 300 mg twice daily is used for gallstone prevention.
Frequency The total daily amount must be administered in two to four divided doses to be taken throughout the day.
Timing with Food The medication must be taken with food for all approved uses to ensure proper absorption and effectiveness.

Procedural and Duration Context

For most conditions, the total prescribed dose is taken in divided portions, and solid forms must be swallowed whole. Scored tablets (e.g., 500 mg) may be broken in half to achieve the precise prescribed quantity, but the pieces must not be chewed.

The required duration of therapy varies significantly by indication. For PBC, treatment is part of a long-term therapeutic plan. For gallstone dissolution, therapy can extend for many months—often up to two years—and is officially recommended to continue for three months after imaging confirms the complete dissolution of the stones. If a dose is missed, instructions advise taking it as soon as remembered, but caution against taking a double dose if the next scheduled time is near.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Adursal

This overview summarizes the official clinical research and scientific studies that have examined Adursal (Ursodiol), describing the types of evidence available for its primary uses. This information is purely descriptive and does not offer clinical advice, dosing instructions, or safety guidance.


Evidence for Use in Primary Biliary Cholangitis (PBC)

The research foundation for Adursal in Primary Biliary Cholangitis (PBC) consists of well-established study designs. Researchers utilized Randomized Controlled Trials (RCTs) to compare patients taking Adursal against those taking an inactive substance (placebo). These short-term trials were complemented by long-term observational studies and pooled analyses, which combine data from multiple RCTs to contribute to the broader evidence landscape.

The studies monitored a range of crucial outcomes. Researchers primarily focused on hard clinical endpoints, such as tracking the long-term rate of liver transplant-free survival and overall patient outcomes. They also examined surrogate biochemical markers of liver health, like serum levels of Alkaline Phosphatase and Bilirubin, which are outcomes monitoring physiological strain or stress. Findings from these analyses reported data showing patterns related to these long-term clinical and biochemical outcomes.


Evidence for Use in Cholesterol Gallstone Management

Research into Adursal's role in gallstone management was evaluated in specific settings, including for the dissolution of small, non-calcified cholesterol gallstones and for prevention in high-risk groups, such as obese patients undergoing rapid weight loss. The primary research used placebo-controlled RCTs to isolate the measured changes.

These studies examined structural outcomes, such as the achievement of complete gallstone dissolution (clearance) or the failure to form new stones. Researchers also monitored biochemical outcomes related to the saturation of cholesterol in the bile, a factor studied in relation to structural changes. Controlled trials reported physical changes in bile composition.


Areas of Research Uncertainty and Study Limitations

The evidence highlights what is known — and what is still uncertain — about Adursal. One significant limitation is the frequent reliance on surrogate markers (like liver enzyme changes) in place of definitive clinical outcomes. While these markers was associated with outcomes, they are not considered a standalone measure of long-term patient outcomes.

Long-term outcomes are not fully established by short-term trials alone. Data for certain groups remain insufficient, and the results apply only to the populations studied, meaning the applicability to individuals outside of controlled trial settings cannot be predicted. The research contributes to the broader evidence landscape, but the scientific community acknowledges that research is ongoing to address these uncertainties.

Frequently Asked Questions (FAQ)

Common questions about Adursal (FAQ)

Q: Can Adursal potentially affect liver function and require regular blood tests?

Yes, official product information indicates that Adursal can affect liver health markers. For this reason, liver function tests (such as ALT, AST, and Bilirubin levels) are typically monitored every month for the first three months of therapy, and then every six months thereafter.

Q: Does Adursal interact with any commonly prescribed medications for blood pressure?

Regulatory documents state that Adursal may decrease the absorption and resulting systemic exposure of certain calcium channel blockers, such as Nitrendipine, which is used to manage blood pressure. Official information notes that co-administration may require dose adjustments as determined by a prescribing professional.

Q: Is Adursal considered suitable for older adults (seniors)?

The medication is approved for use in adults. However, official studies did not include sufficient numbers of patients aged 65 and over to specifically determine whether they respond differently compared to younger patients.

Q: Why do some official warnings mention watching for signs of an allergic reaction to Adursal?

Official information lists hypersensitivity to the drug as a contraindication (a reason the drug should not be used). Certain reported adverse events, such as hives (Urticaria) and severe itching (Pruritus), are symptoms that may be associated with an allergic reaction.

Q: What are the serious signs of liver damage that patients should be aware of while taking Adursal?

Serious adverse reactions described in regulatory documents include a clinically significant increase in liver enzymes and symptoms of cholestasis (bile flow impairment), such as jaundice (yellowing of the skin or eyes). Severe upper right abdominal pain is also a serious adverse reaction in regulatory documentation.

Q: Is it true that Adursal works by blocking a specific enzyme in the body?

No. Official documents describe Adursal's mechanism of action as primarily working to alter the composition of bile and provide a protective effect for liver cells. It is not described as working by blocking a specific enzyme.

Q: Is abdominal pain a common side effect of Adursal, and when should it be a concern?

General abdominal pain is listed as a very common side effect in clinical reports. However, severe right upper quadrant abdominal pain is listed separately as a serious adverse reaction that is documented as requiring evaluation.

Q: Is the active ingredient in Adursal also available under different brand names?

Yes. The active ingredient, Ursodiol (Ursodeoxycholic Acid), is marketed under various brand names and is also available as a generic medicine from different manufacturers.

Q: Does Adursal need to be taken at the same time every day?

Official administration guidelines state that the total daily dose is administered in two to four divided doses throughout the day and that the medication is taken with food. While not explicitly required, taking the divided doses consistently helps ensure stable drug levels are maintained.

Q: Is it possible for Adursal to cause unexplained muscle pain or weakness?

Yes, regulatory documents list muscle aches, muscle or bone pain, and weakness as side effects that have been reported in clinical data.

Q: Why is feeling unusually tired or fatigued listed as a possible side effect of Adursal?

Fatigue and unusual tiredness or weakness are listed as commonly reported side effects in the clinical reports section of the product labeling.

Q: Does Adursal have any known interactions with common over-the-counter pain relievers?

Official labeling does not report any specific interactions between Adursal and common over-the-counter pain relievers such as acetaminophen or ibuprofen.

Q: Are there any known food or drink restrictions while taking Adursal (e.g., specific juices)?

Official guidelines emphasize that the medication is taken with food to ensure proper absorption. The labeling contains no explicit restrictions on specific foods, drinks, or juices (such as grapefruit juice).

Q: Can individuals who have kidney problems use Adursal safely?

Adursal is primarily processed and eliminated through the liver and biliary system, with a very small amount handled by the kidneys. Therefore, regulatory information suggests that no dose adjustment is typically required for patients who have renal impairment.

Q: What are the general expectations for how quickly Adursal starts to show an effect?

Official clinical pharmacology information indicates that the therapeutic bile acid concentrations of Adursal reach a steady-state in about 3 weeks with repeated dosing. However, for specific conditions like gallstone dissolution, a therapeutic effect may take many months to observe.

Q: If someone is feeling better, does that mean they can stop taking Adursal?

No. Official regulatory guidance emphasizes that treatment for certain conditions, such as Primary Biliary Cholangitis (PBC), is a long-term therapeutic plan. For gallstone dissolution, therapy is recommended to continue for three months after imaging confirms the complete clearance of the stones.

Q: Does Adursal have any potential effects on blood sugar levels or diabetes management?

Yes, regulatory documents list elevated blood glucose (hyperglycemia) as a reported adverse event in some clinical data.

Q: Can Adursal cause headaches or dizziness upon standing?

Headache and dizziness are listed as very common to common side effects in clinical reports.

Q: Is weight change (gain or loss) a possible effect of Adursal?

Regulatory documents report that unusual weight gain or loss and rapid weight gain have been reported in clinical data, though the exact incidence is not known.

Q: Do patients need to be monitored for a change in heart rhythm while on Adursal?

Reported side effects related to heart rhythm include fast heartbeat and irregular or pounding heartbeats.

Q: Does taking Adursal affect a person’s ability to drive or operate heavy machinery?

Patient information includes a caution that individuals should exercise care when driving or operating machinery until the effect of the medicine is known, due to the possibility of certain side effects like dizziness.

Q: What happens in the body when Adursal is stopped abruptly?

Official guidance stresses that Adursal is a long-term therapy for certain conditions. Abrupt discontinuation is addressed in regulatory warnings because stopping treatment may lead to a deterioration of liver health markers.

Q: Is Adursal available as a generic medicine or only under its brand name?

The active ingredient, Ursodiol, is listed in the FDA's Orange Book and is available from various manufacturers as both a generic medicine and under different brand names.

How should Adursal be stored and disposed of?

How to Store and Dispose of Adursal

Adursal (ursodiol) must be stored strictly according to regulatory specifications to ensure stability and potency.

Storage Requirements

  • Temperature: Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), allowing for temporary excursions up to 30 C (86 F). The product must be kept from freezing.
  • Container and Protection: Keep Adursal in its original, tightly closed, light-resistant container, stored away from excess moisture and direct light.
  • Child Safety: The medicine must be stored out of the sight and reach of children.

Stability and Disposal

Scored tablets, if broken, should be used within 28 days. Disposal of any unused or expired product must be carried out in accordance with local waste disposal regulations. Consult a healthcare professional or pharmacist for specific disposal advice if local take-back programs are not available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adursal found in:

A-Z Index: